56367-24-9

Usage

Uses

3-Isopropyl-1H-pyrazol-5-amine

InChI:InChI=1/C6H11N3/c1-4(2)5-3-6(7)9-8-5/h3-4H,1-2H3,(H3,7,8,9)

Upstream product

• 2861-04-3 4-methyl-2,3-pentadienenitrile 
• 29509-06-6 4-methyl-3-oxopentanonitrile 

Downstream Products

• 1616085-93-8 2-chloro-N-(5-isopropyl-1H-pyrazol-3-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-amine 
• 1403758-06-4 1-(4-((5-isopropyl-1H-pyrazol-3-yl)amino)phenyl)butan-1-one 
• 1574358-73-8 3-isopropyl-1-(3-(2-morpholinoethoxy)phenyl)-1H-pyrazol-5-amine 

Relevant academic research and scientific papers

Application of 5-aminopyrazole compounds to plant growth regulation aspect

The invention discloses application of 5-aminopyrazole compounds to plant growth regulation aspect in the technical field of pesticide compounds, in particular to application of the 5-aminopyrazole compounds shown by the formula to the plant growth regulation aspect, particularly the application to the plant growth inhibition. The formula I is shown in the description. The compound shown in the formula I can be used as a weedicide; weeds in places such as highway and railway can be killed through regulating the concentration of the 5-aminopyrazole compounds, wherein the R1 is hydrogen or alkylor phenyl or substituted phenyl; R2 is alkyl; R3 is hydrogen or halogen.

Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy

We synthesized a library of aminopyrazole analogs to systematically explore the hydrophobic pocket adjacent to the hinge region and the solvent exposed region of cyclin dependent kinases. Structure-activity relationship studies identified an optimal substitution for the hydrophobic pocket and analog 24 as a potent and selective CDK2/5 inhibitor.

Direct synthesis of pyrazoles from esters using tert-butoxide-assisted C-(C=O) coupling

This paper describes the direct synthesis of pyrazoles from esters that comprises two sequential reactions: tert-butoxide-assisted C-C(=O) coupling reaction to yield β-ketonitrile or α,β-alkynone intermediates, and condensation by hydrazine addition. The method reported allows for easy control of the regioselectivity and structure of substituents at N-1, C-3, C-4 and/or C-5 positions.

Pyrazolotriazines as inhibitors of nucleases

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3 and R4 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF

Fused pyrimidine compounds as kinase inhibitors, such as multi-kinase inhibitors, are provided. Fused pyrimidine compounds as IGF-IR inhibitors are provided. The compounds may be used in a method of treating cancer. Pharmaceutical compositions containing a fused pyrimidine compound and a pharmaceutically acceptable carrier are also provided, as are kits containing a fused pyrimidine compound or salt thereof and instructions for use, e.g., in a method of treating cancer.

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as antiproliferative agents for the treat

INHIBITORS OF AKT ACTIVITY

The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Methods of Using IGFIR and ABL Kinase Modulators

The invention provides methods of treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell t

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.